Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.05. | IDL Diagnostics AB: AroCell changes name to IDL Diagnostics AB | 119 | GlobeNewswire (Europe) | AroCell AB (publ) today announces that the company will change its name to IDL Diagnostics AB in accordance with a resolution made at AroCell's Annual General Meeting on 15 May 2025. On 27 May, trading... ► Artikel lesen | |
26.05. | Change of company name and ticker for AroCell AB | 197 | GlobeNewswire | As from May 27, 2025, AroCell AB will change company name to IDL Diagnostics AB (publ).
Old company name: AroCell AB
New company name: IDL Diagnostics AB (publ)
Old ticker: AROC
New... ► Artikel lesen | |
IDL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
15.05. | AroCell AB: Report from AroCell's Annual General Meeting 2025 | 200 | GlobeNewswire (Europe) | (Available in Swedish only)
Nedan redovisas de väsentliga beslut som fattades vid AroCells årsstämma tidigare idag den 15 maj 2025. Stämman hölls i AroCells lokaler i Stockholm samt genom poströstning.... ► Artikel lesen | |
07.05. | AroCell AB: AroCell AB (publ) Interim Report January 1st to March 31st, 2025 | 91 | GlobeNewswire (Europe) | A word from the CEO"AroCell experienced a high level of activity during the first quarter of the year. Sales continue to grow in both oncology and bacteriology and order intake is also showing a continued... ► Artikel lesen | |
11.04. | AroCell AB: AroCell's board of directors proposes to the AGM that the parent company change its name to IDL Diagnostics AB | 104 | GlobeNewswire (Europe) | The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics... ► Artikel lesen | |
19.02. | AroCell AB: AroCell AB (publ) Interim Report January 1st to December 31st, 2024 | 140 | GlobeNewswire (Europe) | A word from the CEO" It is with great pleasure that I present this year's results. The year has been characterized by continuous and strong sales growth. We have increased our sales by over 33% compared... ► Artikel lesen | |
08.01. | AroCell AB: Ellen Dittberner returns as CFO at AroCell on January 13, 2025 | 107 | GlobeNewswire (Europe) | AroCell AB is pleased to announce that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has... ► Artikel lesen | |
24.10.24 | AroCell AB: AroCell AB (publ) Interim Report January 1st to September 30th, 2024 | 232 | GlobeNewswire (Europe) | CEO's statement"It is with great pleasure that I present another strong quarterly report. We have achieved positive net earnings, excluding goodwill amortization, and are now well on our way to sustainable... ► Artikel lesen | |
21.08.24 | AroCell AB: AroCell AB (publ) Interim Report January 1st to June 30th, 2024 | 171 | GlobeNewswire (Europe) | CEO's statement"I am very pleased to announce that our growth focus within existing markets is yielding results. We are experiencing a significant increase in sales while simultaneously adjusting our... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 91,91 | +0,22 % | Gilead Sciences: Tage der Entscheidung | Woche der Entscheidung für Gilead Sciences: Bis einschließlich morgen (19. Juni) will die US-Zulassungsbehörde FDA entscheiden, ob die neuartige HIV-Präventionstherapie des Unternehmens eine Vertriebsgenehmigung... ► Artikel lesen | |
TILRAY BRANDS | 0,312 | -0,51 % | Tilray Brands, Inc. - 8-K, Current Report | ||
VERTEX PHARMACEUTICALS | 382,40 | -0,17 % | Vertex Pharma's Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence | ||
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
TONIX PHARMACEUTICALS | 28,800 | +1,41 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals-Aktionäre genehmigen alle Vorschläge auf Jahreshauptversammlung | ||
BAYER | 26,900 | +2,53 % | Pharma-Revolution 2025: Warum Novo Nordisk, NetraMark Holdings und Bayer durch KI-Effizienz Ihre Rendite verdoppeln | Die Pharmabranche befindet sich 2025 im digitalen Umbruch. Künstliche Intelligenz entschlüsselt Wirkstoffe in Rekordzeit, Big Data treibt personalisierte Therapien voran und Blockchain sichert Lieferketten.... ► Artikel lesen | |
MERCK KGAA | 112,00 | +2,42 % | Merck KGaA: Hier dürften sich die Bären entscheiden | Die Merck-Aktie ist seit Herbst 2024 ein perfektes "Opfer" des bärischen Lagers. Obwohl die Analysten durchweg höhere Kursziele sehen, fiel die Aktie wie an der Schnur gezogen. Aber irgendwann ist jeder... ► Artikel lesen | |
NOVO NORDISK | 61,55 | +1,92 % | Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly's Mounjaro launch | ||
ASTRAZENECA | 123,00 | +0,65 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Die beschleunigte US-Zulassung von Datroway gegen... ► Artikel lesen | |
EYENOVIA | 5,390 | 0,00 % | Eyenovia, Inc.: Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program | ||
ROCKET LAB | 28,400 | +0,32 % | AST SpaceMobile Stock Downgraded, Rocket Lab Prepares Electron Launch: Space Stock Countdown | ||
PFIZER | 20,795 | +0,19 % | Pfizer, AbbVie und Co unter Druck: Trump mit dem nächsten Hammer? | US-Präsident Donald Trump will der Pharma-Industrie weiter an den Kragen gehen. Laut Kreisen möchte der Republikaner die Pharmawerbung in den Vereinigten Staaten einschränken. Nach einer generellen... ► Artikel lesen | |
METSERA | 29,020 | 0,00 % | Metsera stock initiated at overweight by Wells Fargo on obesity drug |